Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10

International Journal of Pharmaceutics

Volumn 378, Issue 1-2, 2009, Pages 140-141

  Mizuma, Takashi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Glucuronidation metabolism; Oral bioavailability; Presystemic intestinal availability; Presystemic metabolism

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; RALOXIFENE;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME SUBSTRATE; FIRST PASS EFFECT; INTESTINE ABSORPTION; LIVER METABOLISM; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; LIVER; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 67650591016     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.05.044     Document Type: Article

References (10)

1. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10 (1993) 1093-1095
2. Kemp D.C., Fan P.W., and Stevens J.C. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos. 30 (2002) 694-700
3. Mizuma T. Kinetic impact of presystemic intestinal metabolism on drug absorption: experiment and data analysis for the prediction of in vivo absorption from in vitro data. Drug Metab. Pharmacokinet. 17 (2002) 496-506
4. Mizuma T. Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol SULT1A3 substrate. J. Pharm. Sci. 97 (2008) 5471-5476
5. Mizuma T., Koyanagi A., and Awazu S. Intestinal transport and metabolism of glucose-conjugated kyotorphin and cyclic kyotorphin: metabolic degradation is crucial to intestinal absorption of peptide drugs. Biochim. Biophys. Acta 1475 (2000) 90-98
6. Mizuma T., Tsuji A., and Hayashi M. Does the well-stirred model assess the intestinal first-pass effect well? J. Pharm. Pharmacol. 56 (2004) 1597-1599
7. Tukey R.H., and Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 581-616
8. U.S. Food and Drug Administration. (1999a) Evista medical review, http://www.fda.gov/cder/foi/nda/99/20815S3_Evista_medr_P1.pdf.
9. U.S. Food and Drug Administration. (1999b) Evista printed labeling, http://www.fda.gov/cder/foi/nda/99/20815S3_Evista_prntlbl_P1.pdf.
10. Wu C.Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., and Wacher V.J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 58 (1995) 492-497